Kane Biotech Announces Special Meeting of Shareholders

Company Overview - Kane Biotech Inc. is a biotechnology company focused on the research, development, and commercialization of technologies and products aimed at preventing and removing microbial biofilms [3] - The company holds a portfolio of 80 patents and patents pending, along with trade secrets and trademarks [3] - Kane Biotech's product offerings include StrixNB™, DispersinB®, Aledex™, and several others [3] Leadership Update - A special meeting of shareholders is scheduled for February 20, 2024, to consider the election of Dr. Robert Huizinga as an additional director [1] - Dr. Huizinga has extensive experience in the pharmaceutical industry, having previously served as Executive Vice-President of Aurinia Pharmaceuticals Inc., where he led the clinical development of voclosporin, achieving first-year sales of $100 million USD [2] - He has been a member of Kane Biotech's Scientific Advisory Board since 2018 [2]